The molecular pharmacology of L-deprenyl

European Journal of Pharmacology: Molecular Pharmacology

Volumn 226, Issue 2, 1992, Pages 97-108

  Gerlach, Manfred ^a,b   Riederer, Peter ^a   Youdim, Moussa B H ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

L Deprenyl; Monoamine oxidase inhibitors; Neuroprotective mechanisms; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; FLAVINE ADENINE NUCLEOTIDE; LEVODOPA; OXIDOPAMINE; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL ARTICLE; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; HUMAN; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; SUPPORT, NON-U.S. GOV'T;

EID: 0026772799     PISSN: 09224106     EISSN: None     Source Type: Journal    
DOI: 10.1016/0922-4106(92)90170-Z     Document Type: Article

References (102)

1. 11C]deprenyl
2. cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties
3. Intranigral iron injection induces behavioural and biochemical parkinsonism in the rat
4. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons
5. The potentiation of the antiakinetic effect after L-dopa treatment by an inhibitor of MAO-B, deprenyl
6. R and L-Deprenyl in Parkinson's disease
7. R treatment in Parkinson's disease: a longterm study
8. Amine oxidase and amine metabolism
9. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation
10. (−)-Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats
11. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
12. (−)-Deprenyl can induce soluble superoxide dismutase in rat striata
13. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence
14. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover
15. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys
16. Ro-19-6327: a novel highly selective and reversible MAO-B inhibitor
17. Some basic aspects of reversible inhibitors of monoamine oxidase-A
18. The turnover of the A- and B-forms of monoamine oxidase in rat liver
19. A monoclonal antibody elicited to human platelet monoamine oxidase, isolation and specificity for human monoamine oxidase B but not A
20. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B
21. Interactions of monoamine oxidase with substrates and inhibitors
22. Does the B form selective monoamine oxidase inhibitor deprenyl lose selectivity by long term treatment?
23. Cumulative effects of irreversible MAO inhibitors in vivo
24. Pharmacology of selective propargyl ‘suicide’ inhibitors of monoamine oxidase
25. Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B
26. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B
27. Monoamine oxidase A and B: a useful concept?
28. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline
29. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
30. Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons
31. Dopamine is a monoamine oxidase-B substrate in man
32. Deprenyl as symptomatic therapy in Parkinson's disease
33. Auto-oxidation versus covalent binding quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro
34. The kinetics of inhibition of type-B monoamine oxidase by clorgyline, pargyline and (−)-deprenyl
35. Effect of monoamine oxidase inhibition by clorgyline, deprenyl or tranylcrypromine on 5-HT concentration in rat brain and hyperactivity following subsequent tryptophan administration
36. Evidence that dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of enzyme inhibition necessary to increase functional activity of dopamine and 5-hydroxytryptamine
37. Pharmacological modifications of the neurotoxic action of the noradrenaline neurotoxin DSP-4 on central noradrenaline neurons
38. Further studies on generation of hydrogen peroxide by 6-hydroxydopamine: potentiation by ascorbic acid
39. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors
40. Monoamine oxidase and the bioactivation of MPTP and related neurotoxins: relevance to DATATOP
41. Some observations upon a new inhibitor of monoamine oxidase in brain tissue
42. Effects of the noradrenaline neurotoxin DSP-4 on the postnatal development of noradrenaline neurons in the rat
43. Selective acetylenic ‘suicide’ and reversible inhibitors of monoamine oxidase types A and B
44. Substrate specifities of the two forms of monoamine oxidase
45. Analysis of the pharmacological effect of selective monoamine oxidase inhibitors
46. The possible mechanisms of action of (−)-deprenyl in Parkinson's disease
47. Structure-activity relationships of the selective inhibitors of MAO-B
48. Deprenyl (selegiline) the history of its development and pharmacological action
49. The pharmacology of (−)-deprenyl
50. R) facilitates the activity of the nigrostriatal dopaminergic neuron
51. The striatal dopamine dependency of life span in male rats, longevity study with (−)deprenyl
52. Some puzzling effect of monoamine oxidase inhibitors
53. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer
54. Novel (−)-deprenyl-derived selective inhibitors of B-type monoamine oxidase, the relation of structure to their action
55. Demonstration of monoamine oxidase-A and -B in the human brainstem by a histochemical technique
56. Expression of functional human monoamine oxidase A and B cDNAs in mammalian cells
57. Human monoamine oxidase A and B genes map to Xp11.23 and are deleted in paticat with Norrie disease
58. Pargyline prevents MPTP-induced parkinsonism in primates
59. Comparative pharmacological analysis of the optical isomers of phenylisopropylmethylpropinylamine (E-250)
60. Relations between the degree of monoamine oxidase inhibition and some psychopharmacological responses to monoamine oxidase inhibitors in rats
61. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism
62. 3H]Harman labels selectively and with high affinity the active site of monoamine oxidase (EC 1.4.3.4) subtype A (MAO-A) in rat, marmoset, and pig
63. The action of acetylenic inhibitors on mitochondrial monoamine oxidase: structure of the flavin site in the inhibited enzyme
64. Bovine liver monoamine oxidase, a modified purification procedure and preliminary evidence for two subunits and one FAD
65. The excitatory amino acid receptors: their classes, pharmacology and distinct properties in the function of the central nervous system
66. 6-Hydroxydopamine release iron from ferritin and promotes territin dependent lipid peroxidation
67. The deamination of dopamine by human brain monoamine oxidase specificity for the two enzyme forms in seven brain regions
68. 11C-L-deprenyl
69. The rational design of suicide substrates of amine oxidase
70. Effect of deprenyl on the progression of disability in early Parkinson's disease
71. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease
72. 2-Phenylethylamine: a modulator of catecholamine transmission in the mammalian central nervous system?
73. Regional effects of 6-hydroxydopamine (6-OHDA) on free radical scavengers in rat brain
74. Rates of recovery of irreversibly inhibited monoamine oxidase: a measure of enzyme protein turnover
75. cal inhibitors
76. Deprenyl is metabolized to methamphetamine and amphetamine in man
77. Amphetamine and phenylethylamine in post-mortem Parkinson's brain after (−)-deprenyl administration
78. MAO-B-inhibitor selegiline (R-(−)-deprenyl): a new therapeutic concept in the treatment of Parkinson's disease
79. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl
80. On the mode of action of L-deprenyl in the human central nervous system
81. Monoamine oxidase and parkinsonism
82. Long-term effects of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurons in the rat brain and heart
83. Mechanism of action of 6-hydroxydopamine
84. Monoamine oxidase from beef liver mitochondria: simplified isolation procedure, properties and determination of its cysteinyl flavin content
85. 14C]-deprenyl
86. Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline
87. Evidence that deprenyl, a type B monoamine oxidase inhibitor, is an indirectly acting sympathomimetic amine
88. Active site-directed irreversible inhibitors of monoamine oxidase
89. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism
90. Amphetamine: differentiation by D and L isomers of behaviour involving brain norepinephrine or dopamine
91. The effect of deprenyl (Selegiline) on the natural history of Parkinson's disease
92. Kinetic mechanism and enzyme function
93. The kinetics of monoamine oxidase inhibitors in relation to their clinical behaviour
94. Specifities of the two forms of monoamine oxidase
95. The influence of intraneuronal monoamine oxidase on neuronal net amine uptake of noradrenaline and on sensitivity to noradrenaline
96. Deprenil, loss of selectivity for inhibition of B-type MAO after repeated treatment
97. Monoamine oxidase A from human placenta and monoamine oxidase B from buvine liver both have one FAD per subunit
98. Effect of the glycene prodrug milacemide (2-N-pentylaminoacelamide) on calc-cholamine secretion from isolated adrenal medulla chromaffin cells
99. 14C)-deprenyl
100. Monoamine oxidase
101. The role of monoamine oxidase, iron-melanin interaction and intracellular calcium in Parkinson's disease
102. MDL 72.974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for the use in Parkinson's disease